Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.

Burke PJ, Hamilton JZ, Pires TA, Setter JR, Hunter JH, Cochran JH, Waight AB, Gordon KA, Toki BE, Emmerton KK, Zeng W, Stone IJ, Senter PD, Lyon RP, Jeffrey SC.

Mol Cancer Ther. 2016 May;15(5):938-45. doi: 10.1158/1535-7163.MCT-16-0038. Epub 2016 Mar 4.

2.

Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.

Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, Law CL.

Cancer Res. 2016 May 1;76(9):2710-9. doi: 10.1158/0008-5472.CAN-15-1795. Epub 2016 Feb 26.

3.

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index.

Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD.

Nat Biotechnol. 2015 Jul;33(7):733-5. doi: 10.1038/nbt.3212. Epub 2015 Jun 15.

PMID:
26076429
4.

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates.

Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson ME, Balasubramanian CL, Duniho SM, Leiske CI, Li F, Senter PD.

Nat Biotechnol. 2014 Oct;32(10):1059-62. doi: 10.1038/nbt.2968. Epub 2014 Sep 7.

PMID:
25194818
5.

Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.

Lyon RP, Meyer DL, Setter JR, Senter PD.

Methods Enzymol. 2012;502:123-38. doi: 10.1016/B978-0-12-416039-2.00006-9.

PMID:
22208984

Supplemental Content

Loading ...
Support Center